The EPS projection of Bio-Techne Corp (NASDAQ:TECH) for quarter ended 2016-09-30 is $0.8. A week before, the EPS forecast was $0.8 against target of $0.8, a month earlier. This estimate stood at $0.8 60 days earlier versus forecast of $0.8 90 days earlier, confirming a deviation of 0%.
Bio-Techne Corp (NASDAQ:TECH) reported that 18 days ago, the positive EPS revisions were 0 and negative revisions at 0.
In last week, the per-share earnings was lowered 0 times and 0 times positively. In last 120, 60, 30 and 90 days the positive revisions were 0, 0, 0 and 0, respectively.
The downgrade of EPS estimates for Bio-Techne Corp (NASDAQ:TECH) in the preceding 120, 60, 30 and 90 days were 0, 0, 0 and 0, in that order.
As per the latest update, for the quarter closed 3, the EPS estimate of Bio-Techne Corp (NASDAQ:TECH) was $0.8. This projection was computed after accounting 3 calls. As reported on 2016-05-03 the EPS was $0.97. The change was $0.12, demonstrating a percentage deviation of 14.12%. The projections confirmed a standard deviation of 0.03.
Quarterly Sales Estimates
For the fiscal 2017, the yearly sales target for Bio-Techne Corp (NASDAQ:TECH) stands at $136.638 and the median estimate at $136.78. Almost 5 analysts announced their estimates.
The highest estimate is $140.4 while the lowest target is $132.53 showing standard deviation of 2.984%.
As many as 5 analysts released sales estimates reised in upside while 5 reduced sales estimates, demonstrating a deviation of 0%.
In last month, 5 revised sales number projection on upside while 5 lowered the sales target, demonstrating a deviation of 0.123%.
A quarter ago, 5 hiked sales estimations and 5 reduced sales forecast. Bio-Techne Corp (NASDAQ:TECH) stated that the change in forecast was 1.245%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...